---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-088341"
form_type: "8-K"
ticker: "MDAI"
cik: "0001833498"
company_name: "Spectral AI, Inc."
filed_at: "2026-08-12T20:03:02+00:00"
generated_at: "2026-08-12T20:04:18.318008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spectral AI Q2 loss narrows to $4.2M; FDA-cleared DeepView targets first sales by year-end

## Summary
- Q2 2026 R&D revenue $3.5M vs $5.1M YoY; gross margin 31.6% vs 45.2% on BARDA cost-share.
- Net loss $4.2M ($0.13/share) vs $8.0M loss ($0.31) YoY; adjusted EBITDA loss $(3.5)M vs $(1.7)M.
- Cash $14.0M at June 30, 2026; drew $6.5M under Avenue Capital credit facility post-FDA clearance.
- FDA De Novo clearance for DeepView burn indication received May 2026; first U.S. commercial sales targeted by year-end 2026.
- March 2026 BARDA advanced funding of $31.7M; new CFO David McGuire and CCO Darcy Bajko appointed.

## SEC filing metadata
- accession: 0001213900-26-088341
- form_type: 8-K
- ticker: MDAI
- cik: 0001833498
- company_name: Spectral AI, Inc.
- filed_at: 2026-08-12T20:03:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833498/000121390026088341/0001213900-26-088341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833498/000121390026088341/ea0301807-8k_spectral.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-088341
- JSON: https://secwatch.observer/filing/0001213900-26-088341.json
- Plain text: https://secwatch.observer/filing/0001213900-26-088341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.